Paracetamol and Ibuprofen Usage during Infancy and the Risk of Eczema and Bronchiolitis
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on April 1st, 2026
|
|
Eczema and bronchiolitis are common atopic conditions that have become more prevalent in developing countries, which have imposed a significant public health burden to these nations. A couple of previous observational studies had found that usage of paracetamol during infancy can increase the risk of eczema and other atopic disease. However, these studies are less concrete due to their design, so a randomized control study was conducted to better understand the risk of eczema in infants who were treated with paracetamol.
|
Usage of Finerenone in Patients with Chronic Kidney Disease and Type 1 Diabetes
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 25th, 2026
|
|
In recent years, the human monkeypox virus has posed a significant public health challenge. Being a relative of the eliminated smallpox virus, there had been interest in utilizing smallpox therapy for monkeypox. A study recently published in the New England Journal of Medicine that tested the effectiveness of tecovirimat in treating human monkeypox virus infection.
|
Tirzepatide versus Dulaglutide in Preventing Cardiovascular Disease
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 26th, 2026
|
|
Usage of GLP-1 agonists had become very common as a means to control body weight, manage diabetes, and prevent other obesity-related health complications. Some of these complications are cardiovascular events such as myocardial infarction and stroke. With funding from Eli Lilly, a study was conducted to compare tirzepatide to dulaglutide in preventing cardiovascular disease.
|
Weight Management with GLP-1 Receptor Agonist, Orforglipron
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on December 3rd, 2025
|
|
Overweight and obesity substantially raise the risk of numerous chronic diseases. GLP-1 receptor agonists have been shown to improve glycemic control, support weight loss, and lower cardiovascular risk. Orforglipron, a GLP-1 agonist already used for type 2 diabetes, was evaluated in a study funded by Eli Lilly to explore its effectiveness for weight management.
|
Prevent Stroke Recurrence in Diabetic Patients with Liraglutide
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 28th, 2025
|
|
Individuals with diabetes face an elevated risk of ischemic stroke, and they are more likely to experience recurrent events. Prior research suggests that glycemic control alone-whether through insulin or sulfonylureas-does not fully account for this risk, indicating that additional mechanisms such as inflammation or insulin resistance may contribute to recurrence. With support from the Chinese government, researchers conducted a study to evaluate whether liraglutide could reduce the risk of stroke and transient ischemic attack in patients with diabetes.
|
Weight Management with Reduced-Dose Oral Semaglutide
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 10th, 2025
|
|
Semaglutide, initially approved as a subcutaneous injection for type 2 diabetes, is now also available in an oral formulation. Beyond glycemic control, semaglutide has been shown to promote significant weight reduction. A recent Novo Nordisk–funded study evaluated the effect of a lower oral dose of semaglutide in managing obesity.
|
Managing Type 2 Diabetes with Oral GLP-1 Agonist, Orfoglipron
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 8th, 2025
|
|
Activation of GLP-1 receptors is a well-established strategy for managing type 2 diabetes, with agents such as semaglutide and tirzepatide also showing benefits for weight loss and cardiovascular health. However, their use is complicated by the need for injection. Orfoglipron, a small-molecule oral GLP-1 receptor agonist, offers a potentially simpler alternative. Supported by Eli Lilly, a study was conducted to evaluate its efficacy in type 2 diabetes.
|
Combining Semaglutide and Cagrilintide for Weight Management
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 8th, 2025
|
|
In addition to lifestyle and dietary change, obesity can also be managed with pharmacotherapy options. Semaglutide, first used for diabetes, had been implemented for weight management. With the medication yielding promising results, there had been a continuous push to explore other approaches. A study, funded by Novo Nordisk, was conducted to explore the usage of semaglutide in combination with cagrilintide to manage obesity.
|
Combination Therapy of Finerenone and Empagliflozin to Manage Kidney Health in Patients with Type 2 Diabetes and Chronic Kidney Disease
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 1st, 2025
|
|
Sodium–glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists are frequently used in patients with chronic kidney disease and type 2 diabetes. The effectiveness of these monotherapy is clearly understood, but little is known about the combination effect. With funding from Bayer, a study was conducted to assess the dual usage of these medications to prevent kidney disease progression.
|
Comparing the Effectiveness of Weekly Insulin Injection to Daily Injection in Managing Type 2 Diabetes
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 11th, 2025
|
|
For patients with type 2 diabetes, insulin injection is recommended if standard glucose-reducing agents cannot achieve effective glycemic control. Daily insulin injections pose significant challenges to patients and can reduce treatment adherence. Eli Lilly had sponsored a study to assess the feasibility of a once-weekly insulin injection to manage blood glucose level.
|
Compare the Weight Reduction Effect between Semaglutide and Tirzepatide
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on July 21st, 2025
|
|
Semaglutide and tirzepatide are novel treatments for diabetes, but due to their clinical benefit, have become popular options in many Western countries. Both of these medications had been associated with significant beneficial metabolic improvement such as weight reduction. A study funded by Eli Lilly recently published in the New England Journal of Medicine had compared the weight management effect between semaglutide and tirzepatide.
|
Mazdutide Demonstrates Promising Weight Loss Results
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on July 4th, 2025
|
|
Many developing and recently developed countries, including Vietnam, are witnessing a rising prevalence of obesity. Glucagon receptor agonists—originally designed to manage type 2 diabetes—have shown potential in supporting weight loss. One such agent, mazdutide, was evaluated for its weight management effects in a study sponsored by Innovent Biologics.
|
Semaglutide Shows Promise in Treating Metabolic Dysfunction-Associated Steatohepatitis
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on June 30th, 2025
|
|
Currently, there is no approved treatment for metabolic dysfunction-associated steatohepatitis. With the condition heavily linked to obesity and diabetes, a study was funded by Novo Nordisk to examine the usage of semaglutide in managing liver health in patients with liver fibrosis and steatohepatitis.
|
Semaglutide Found to Lower Cardiovascular Risk in Patients with Type 2 Diabetes
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on June 27th, 2025
|
|
Those affected with type 2 diabetes experience an elevated risk of cardiovascular disease. Previous study examining the glycemic control of semaglutide, a GLP-1 receptor agonist, had found that it also reduced the risk of cardiovascular disease. To fully explore this relationship, Novo Nordisk had sponsored a study to examine the effect of semaglutide on cardiovascular health in patients with type 2 diabetes.
|
Comparing Oral Glucose-Lowering Agents and Insulin in Gestational Diabetes
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 23rd, 2025
|
|
Insulin has long been the standard therapy for controlling blood glucose in women with gestational diabetes. While oral agents like metformin and glyburide offer a more convenient alternative due to their ease of administration, the American Diabetes Association has advised against their use because of limited data on the long-term safety for offspring. To address this issue, the Australian National Health and Medical Research Council sponsored a study comparing the effectiveness of oral glucose-lowering agents with insulin for managing gestational diabetes.
|
Long-Term Tirzepatide Therapy Yields Significant Weight Loss and Cardiometabolic Benefits
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 9th, 2025
|
|
Obesity is closely linked to the development of type 2 diabetes, a condition marked by significant beta cell dysfunction and insulin resistance. Weight management—whether through pharmacological interventions or lifestyle changes—has been proven to lower the risk of diabetes. Numerous studies have highlighted the weight loss benefits of tirzepatide, and a study funded by Eli Lilly has explored its potential for treating obesity and preventing diabetes.
|
Managing Chronic Kidney Disease with Empagliflozin
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 17th, 2025
|
|
Empagliflozin is a sodium-glucose transporter 2 (SGLT2) inhibitor that is commonly prescribed to manage type 2 diabetes. Independent of the glycemic control effect, previous study had found that SGLT 2 inhibitors can alleviate glomerular hypertension and improve renal function. With funding from Boehringer Ingelheim and Eli Lilly, a recent study explored the usage of empagliflozin in managing chronic kidney disease.
|
Long-term Management of Childhood Obesity with Liraglutide
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 10th, 2025
|
|
Over the past few decades, Vietnam has seen a significant rise in childhood obesity. This trend is especially worrisome because childhood obesity greatly elevates the likelihood of developing lifelong complications such as diabetes and cardiovascular disease. In response to this concern, Novo Nordisk sponsored a study examining the use of liraglutide—a glucagon-like peptide 1 receptor agonist—for weight management in young children.
|
Long-Term Efficacy of Tirzepatide in Managing Heart Failure
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 24th, 2025
|
|
Obesity increases both the risk and severity of heart failure, as adipocytes contribute to a proinflammatory environment that can further damage cardiac tissues. Research has shown that reducing epicardial adipocyte volume through weight loss can mitigate heart failure risk and improve symptoms. Tirzepatide, a widely used antidiabetic medication that aids in weight control, was investigated in an Eli Lilly–funded study for its potential to manage symptoms in individuals with heart failure.
|
Comparing the Efficacy and Safety of Weekly Insulin Efsitora vs. Daily Insulin Degludec in Managing Type 2 Diabetes
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 22nd, 2025
|
|
When traditional glucose-lowering medications are no longer effective at controlling blood sugar levels in patients with type 2 diabetes, insulin injections are used. However, the daily administration of insulin degludec can be challenging, and reducing the frequency of injections may improve treatment adherence. Insulin efsitora is a novel agent with a longer half-life. Eli Lilly funded a study to compare the effectiveness of once-weekly insulin efsitora to the current once-daily insulin degludec in managing blood glucose levels in patients with type 2 diabetes.
|
Effectiveness of GLP-1 Agonists in Managing Alcohol Use Disorder
Topic: PSYCHIATRY, DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 6th, 2025
|
|
GLP-1 agonists, including semaglutide and liraglutide, have proven effective in managing diabetes and obesity. Additionally, biological research has suggested that activating the GLP-1 receptor may help reduce alcohol consumption. A study recently published in the Journal of the American Medical Association explored the potential of using GLP-1 agonists like semaglutide and liraglutide to treat alcohol use disorder.
|
Evaluating the Effectiveness of Semaglutide in Managing Knee Osteoarthritis
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on December 13th, 2024
|
|
Obesity greatly increases the risk of knee osteoarthritis due to the added pressure on the joint and the metabolic dysfunction that triggers inflammation. Previous research has shown that weight management interventions, such as calorie-restricted diets and bariatric surgery, can help reduce the severity of osteoarthritis. Semaglutide, a GLP-1 receptor agonist commonly used to treat diabetes, has demonstrated significant weight loss effects. As a result, a study funded by Novo Nordisk was conducted to evaluate the potential of using semaglutide to manage osteoarthritis.
|
Comparative Effectiveness of Tirzepatide vs. Semaglutide for Weight Reduction in Obese Adults
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 22nd, 2024
|
|
Semaglutide and tirzepatide are two medications widely prescribed for managing type 2 diabetes. Semaglutide works by activating GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP receptors. Both medications help lower cellular glucose absorption and have recently shown potential for weight management. Therefore, a study was conducted to compare the effectiveness of semaglutide and tirzepatide in promoting weight loss.
|
Tirzepatide Shows Promise in Reducing Sleep Apnea Severity and Weight in Obese Patients
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 18th, 2024
|
|
Obstructive sleep apnea is a common condition in individuals with excess weight, often resulting from pharyngeal collapse due to adipose accumulation around the mandibular area. Tirzepatide, a dual agonist for GIP and GLP-1 receptors commonly prescribed for type 2 diabetes, has shown promise in aiding weight loss. Given these findings, Eli Lilly sponsored a study to evaluate tirzepatide’s potential in managing obstructive sleep apnea in individuals with obesity.
|
Lignan-Rich Diet Linked to Reduced Risk of Type 2 Diabetes
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on Octber 7th, 2024
|
|
Previous research has demonstrated that grains, fruits, and vegetables high in polyphenolic lignans can support gut microbiota and lower the risk of cardiovascular and metabolic diseases. However, the impact of a lignan-rich diet on the risk of type 2 diabetes remains unclear. To address this, the National Institutes of Health sponsored a study to explore the connection between lignan consumption and type 2 diabetes risk.
|
Crinecerfont's Potential in Reducing Androgen Levels in Pediatric Congenital Adrenal Hyperplasia
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on September 16th, 2024
|
|
Congenital adrenal hyperplasia is a rare autosomal recessive disorder that impairs the synthesis of cortisol and aldosterone, leading to excessive androgen production. The Endocrine Society recommends hydrocortisone as a standard treatment, but prolonged glucocorticoid use can elevate the risk of metabolic and cardiovascular complications. To address these concerns, Neurocrine Biosciences sponsored a study to evaluate the effectiveness of crinecerfont, a corticotropin-releasing factor receptor antagonist, in managing congenital adrenal hyperplasia.
|
Tirzepatide’s Potential in Reducing Liver Inflammation and Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on September 4th, 2024
|
|
Metabolic dysfunction-associated steatohepatitis (MASH) is linked to an elevated risk of cardiovascular and liver-related complications. Obesity is a significant risk factor for MASH, and previous studies have shown that weight reduction can help resolve the condition. Tirzepatide, a GLP-1 receptor agonist commonly used for diabetes management, also aids in weight loss. To explore its potential in treating MASH, Eli Lilly sponsored a study to investigate the effects of tirzepatide in managing this condition.
|
Evaluating the Efficacy of Semaglutide in Preventing Chronic Kidney Disease Among Type 2 Diabetics
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 7th, 2024
|
|
The risk of chronic kidney disease is significantly higher in patients with type 2 diabetes. Previous studies have shown that those treated with renin–angiotensin system inhibitors and sodium–glucose cotransporter 2 inhibitors have a reduced risk of developing chronic kidney disease. Given the growing popularity of glucagon-like peptide 1 (GLP-1) agonists like semaglutide, a study was conducted to evaluate its impact on the risk of chronic kidney disease in patients with type 2 diabetes.
|
Semaglutide Treatment Improves Clinical Outcomes in Obese Patients with Heart Failure
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 13th, 2024
|
|
The rise in obesity rates has paralleled an increase in the occurrence of heart failure with preserved ejection fraction. Type 2 diabetes (T2DM) is closely linked to both these conditions, and individuals with comorbid heart failure and T2DM experience a greater disease burden and adverse hemodynamics. A recent study aimed to evaluate the potential of Semaglutide, a glucagon-like peptide 1 receptor antagonist commonly prescribed for T2DM, in the management of heart failure with preserved ejection fraction among obese patients.
|
Testosterone Treatment and Fracture Risk in Hypogonadal Men
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 11th, 2024
|
|
Male hypogonadism, in the form of testicular or pituitary dysfunction, is linked to decreased bone density. Previous research indicated that testosterone therapy could potentially reverse this bone loss. However, the earlier study had limitations in duration and sample size. Therefore, a clinical study was initiated to evaluate the efficacy of testosterone in preventing fractures among men with hypogonadism.
|
Long-Term Tirzepatide Treatment Significantly Reduces Body Weight in Participants with Obesity
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 7th, 2024
|
|
Tirzepatide, widely used for diabetes management owing to its insulin-boosting capabilities, has demonstrated a tendency for weight loss in individuals undergoing treatment. Thus, a recent study, featured in the Journal of the American Medical Association, had looked into the impact of Tirzepatide's long-term use on weight management
|
Cardiometabolic benefits and risks of Semaglutide usage in overweight and obese adults without diabetes
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 29th, 2024
|
|
Semaglutide, a glucagon-like peptide 1 (GLP-1), is commonly employed in diabetes management owing to its capacity to stimulate insulin production. Prior research has indicated that the use of GLP-1 diminishes the likelihood of cardiovascular events in diabetic patients. A recently published study in the New England Journal of Medicine seeks to evaluate whether the protective effects observed with Semaglutide in diabetes patients extend to overweight and obese individuals without diabetes.
|
Extending Teplizumab treatment duration to delay progression of type 1 Diabetes
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 24th, 2024
|
|
Type 1 diabetes manifests through an autoimmune attack on pancreatic beta cells responsible for insulin production. Thus, attenuating this immune response could potentially postpone the onset of diabetes. Teplizumab, an antibody capable of binding to CD3 T-cells and inhibiting their response, has received approval from the Food and Drug Administration for short-course treatment in type 1 diabetes. Consequently, the biopharmaceutical company Sanofi sponsored a study to explore the possibility of extending the treatment duration with Teplizumab for additional delays in the progression of type 1 diabetes.
|
Assessing Barticinib role in mitigate autoimmune response and preserve insulin-producing beta cells in patients with newly diagnosed type 1 diabetes
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 19th, 2024
|
|
Individuals afflicted by Type 1 diabetes necessitate insulin supplementation due to their pancreas' incapacity to generate adequate insulin. Studies indicate that safeguarding the residual insulin-producing beta cells can mitigate the severity of the disease. Baricitinib, a JAK inhibitor, has the potential to impede the destructive behavior of autoreactive CD8 T-cells. Consequently, a study aimed to evaluate Baricitinib's capability in impeding autoreactive responses and conserving insulin-producing beta cells.
|
Comparing the effectiveness of Selpercatinib to the standard therapy of Vandetanib or Cabozantinib in treating medullary thyroid cancer
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 8th, 2024
|
|
Medullary thyroid cancer is associated with the uncontrollable cell growth associated with mutation to the RET gene. The condition is currently being treated with either Vandetanib or Cabozantinib. These two agents can bind to and inactivate the RET kinase; however, they caused a lot of side effects and resistance against the agents had been reported. As a result, studies had been conducted to find a better treatment. A paper published in the New England Journal of Medicine had assessed the effectiveness of Selpercatinib, a highly-selective RET kinase inhibitor, in treating medullary thyroid cancer.
|
Utilizing the metabolism effect of Pegozafermin to Address Non-Alcoholic Steatohepatitis (NASH)
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 9th, 2023
|
|
As industrialization and economic development have led to an increase in the rate of obesity, metabolic diseases like non-alcoholic steatohepatitis (NASH) have been on the rise in Vietnam. NASH is characterized by the accumulation of excess fat in the liver, leading to inflammation and potential fibrosis. Pegozafermin, a fibroblast growth factor 21, has the potential to enhance fat catabolism. A recent study aimed to investigate whether pegozafermin's metabolic effects could be harnessed for the treatment of NASH.
|
Semaglutide's Promising Impact on Heart Failure and Obesity
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 6th, 2023
|
|
Obesity is a contributing factor in the onset and progression of heart failure, exacerbating its symptoms and diminishing the overall quality of life. Semaglutide, a medication originally approved for diabetes management known to induce substantial weight loss, was the subject of a study aiming to investigate whether it could improve clinical outcomes for obese patients with heart failure.
|
Daily Oral Orforglipron for Adults with Obesity
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed & translated by Nhi Phuong Quynh Le, B.A
Edited by Dat Tien Nguyen, B.A, ScM. |
Posted on September 29th, 2023
|
|
Obesity is a high-risk disease and a precursor to several diseases relating to the cardiovascular system. Orforglipron is a glucagonlike peptide-1 (GLP-1) receptor agonist orforglipron that can reduce appetite. However, its efficacy and safety is unknown. Thus, a study was conducted to examine the effectiveness and safety of orforglipron for weight reduction in adults with obesity.
|
Possibility of using Retatrutide, a new hormone receptor agonist, to treat obesity
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 8th, 2023
|
|
Retatrutide is a new agent produced by the pharmaceutical company Eli Lilly that can act as an agonist to the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide. Thus, the agent can compete with these molecules for the receptor and block the signaling pathway that would lead to energy storage and fat accumulation. Information about the effectiveness and safety of Retatrutide had recently been published to the New England Journal of Medicine.
|
Improving treatment adherence and glycemic control with weekly insulin injection
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 6th, 2023
|
|
Daily injection of insulin is the current glycemic control strategy in patients living with diabetes; however, treatment adherence is low due to the high frequency. As a result, the effectiveness of daily insulin glargine U100 injection can be lowered. Thus, a study was conducted to assess the feasibility of an once-per-week injection of insulin icodec in controlling blood glucose level.
|
Early detection and treatment of gestational diabetes mellitus
|
Reviewed by translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on July 12th, 2023
|
|
Gestational diabetes is a commonly occurring complication and it can increase the risk of events that can negatively affect the health of both the mother and neonates. Mother had a higher risk of pre-eclampsia and the need of obstetrical intervention. The diabetes can also cause the fetus to grow larger than expected and increase the risk of shoulder dystocia and trauma. Screening and treatment are recommended at gestational week 24, which effectively lower the amount of adverse outcomes. So, a study was performed in Australia and New Zealand to investigate whether treatment at the 20th week can produce the same level of benefit.
|
Weight management with Tirzepatide in people with obesity
TOPIC: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on March 31st, 2023
|
|
Tirzepatide had previously been approved by the Food and Drug Administration to manage type 2 diabetes. The agent mimics the insulinotropic effect of the naturally produced gastric inhibitory polypeptide. Since weight loss was a side effect of the medication when used to manage type 2 diabetes, Eli Lilly had sponsored a study to investigate the potential usage of tirzepatide in managing obesity.
|
Using butyrate supplements to manage obesity in children
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on December 14th, 2022
|
|
Previous metabolomic studies had shown that butyrate is necessary for a healthy gut microbiome. Deficiency of this short chain fatty acid reduces the abundance of certain beneficial bacterial species; resulting in metabolic dysfunction and increasing weight gain. A recent clinical trial tested the efficacy of butyrate supplements in reverting childhood obesity.
|
Finding an alternative purpose for the antihypertensive medication, verapamil, in treating type 2 diabetes
TOPIC: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on December 9th, 2022
|
|
Verapamil is a phenylalkylamine calcium channel antagonist that are frequently used to manage cardiovascular conditions such as arrhythmia, hypertension and angina. As an unintended effect, the agent inhibits the production of proapoptotic thioredoxin-interacting protein (TXNIP). Which overexpression leads to accumulation in the pancreas, resulting in increased oxidative stress that kills beta cells. A recent study has investigated the potential usage of Verapamil in managing type 2 diabetes.
|
The effect of empagliflozin on the gut microbiome and cardiovascular health
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on December 7th, 2022
|
|
Metformin is recommended as the first-line antihyperglycemic agent in most clinical guidelines, including the one published by the World Health Organization. In the United States, empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is recommended by the Food and Drug Administration due to its cardiovascular benefit. A recently published study had investigated the health effect between patients metformin and empagliflozin.
|
The effect of SGLT2i and GLP-1RA combination therapy in weight loss
TOPIC: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on December 5th, 2022
|
|
The anti-diabetic medication, sodium-glucose cotransporter-2 inhibitors (SGLT2i), blocks glucose reabsorption in the kidney; this creates a calorie deficit and leads to weight loss. However, the rate of change is slower than predicted, and the loss can be reverted over time; this can potentially be explained by increased energy intake to compensate for the higher excretion. Glucagon-like peptide 1 receptor agonists (GLP-1RA) is another antidiabetic medication that acts on the central nervous system to suppress appetite. A recent study has investigated whether combining the two medications can create sustainable weight loss.
|
Comparing the effectiveness of 4 classes of medication used to manage diabetes mellitus type 2
Topic: DIABETES & ENDOCRINOLOGY
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on September 23rd, 2022
|
|
According to a clinical guideline published by the Vietnamese ministry of health, metformin, sulfonylurea, dipeptidyl peptidase 4 inhibitor, glucagon-like peptide-1 receptor agonist, and insulin are recommended to manage diabetes mellitus type 2. Each medication has its own contraindication, but little information was provided about the effectiveness of each class of drug. A recent paper published by the collaborative multi-center GRADE Study Research Group had reported that some of the recommended medications are more effective than others in managing diabetes mellitus type 2 (DM2).
|
The gut microbiome of individuals with obesity and type 2 diabetes lacks the commensal bacteria Blautia wexlerae
Topic: Diabetes & Endocrinology
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 22nd, 2022
|
|
Our large intestine contains a collection of commensal bacteria. The interaction between these bacteria and the metabolites they produce has a tremendous impact on our health. A recent study published in Nature found that there is a potential association between the abundance of the commensal bacteria Blautia wexlerae and disorders like obesity and type 2 diabetes mellitus.
|
SARS-CoV-2 infection increases the risk of diabetes onset
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 3rd, 2022
|
|
Even though the acute SARS-CoV-2 infection has been resolved, many patients still report abnormalities with their health. The constellation of these conditions are commonly preferred to as long-COVID, and they can include dysfunction to the respiratory, digestive, neurological system, etc. A recent large cohort study, had recently reported that diabetes might be included into the developing list of post-COVID sequelae.
|